1. 1801 Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). (September 2015) Authors: Untch, M.; Von Minckwitz, G.; Gerber, B.; Eidtmann, H.; Rezai, M.; Fasching, P.A.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; Hanusch, C.; Huober, J.; Solbach, C.; Jackisch, C.; Kunz, G.; Blohmer, J.; Hauschild, M.; Fehm, T.; Nekljudova, V.; Loibl, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). (September 2016) Authors: von Minckwitz, G.; Rezai, M.; Tesch, H.; Huober, J.; Gerber, B.; Zahm, D.M.; Hilfrich, J.; Costa, S.D.; Dubsky, P.; Blohmer, J.U.; Denkert, C.; Hanusch, C.; Jackisch, C.; Kümmel, S.; Fasching, P.A.; Schneeweiss, A.; Paepke, S.; Untch, M.; Burchardi, N.; Mehta, K. Journal: European journal of cancer Issue: Volume 64(2016) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗